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Summary. Cytokines are important soluble signalling 
molecules that dictate and coordinate inflammatory and 
immune responses. Further understanding the role 
of cytokines in the pathobiologic mechanisms of 
pulmonary inflammatory and immune diseases holds the 
key to the development of effective prophylactic and 
therapeutic strategies. In the last several years, the use of 
models of human pulmonary diseases established either 
in normal adult animals, mice deficient for a given 
immune cell type or cytokine, or mice engineered to 
overexpress a given cytokine, has remarkably facilitated 
our understanding of the mechanisms operating 
in human disease. Cytokines that are involved in 
pulmonary inflammatory and immune conditions may be 
generally divided into groups of pro-inflammatory, anti- 
inflammatory and growth-stimulatory cytokines. While 
pro-inflammatory cytokines can be detrimental under 
such severe conditions as endotoxemia and fibrosis, they 
are required in host resistance against infectious agents. 
Anti-inflammatory cytokines play an important role in 
controlling the extent of tissue inflammatory/irnmune 
responses. Overexpression of growth-stimulatory 
cytokines are often directly associated with tissue 
fibrotic responses. In this review, the findings attained 
from experimental models by us and others were 
discussed with emphasis on cellular and histopathologic 
alterations, cytokine-mediated molecular mechanisms 
and the prospects of cytokine-based therapeutic 
strategies. Due to the restricted space, we chose to focus 
only on models for endotoxic lung, endotoxemia, acute 
pulmonary infections by extracellular Gram-negative 
bacteria, chronic pulmonary infections by intracellular 
myco-bacteria, allergic airways inflammation and 
pulmonary fibrosis. 
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Introduction 
Biomedical research aims to understand ourselves in 
order to fulfil1 two goals: to improve the quality of life 
and to better prevent and treat illnesses. Understandably, 
many experiments are either unfeasible or ethically 
unallowable to be carried out in humans (Botting and 
Morrison, 1997). Animal models, particularly, mouse 
models of human pulmonary diseases have been 
instrumental for us not only to understand the disease 
mechanisms but also to evaluate the effectiveness of 
intervention strategies. Cytokines are of paramount 
importance in mediating the cross-communication 
between cells that carry out essential inflammatory and 
immune activities. ~ o s t  cytokines can be released by 
multiple cell types except a few that are restricted 
primarily to lymphocytes, particularly T cells. During 
inflammatory responses elicited by non-immune 
stressors, many c~tokines may be released from multiple 
cellular sources other than lymphocytes. In contrast, 
during host responses elicited by immunogenic antigens, 
antigen-specific T lymphocytes are a prominent source 
of selective cytokines, dependent upon the nature of 
antigens and the genetic background of host. These 
cytokines may be grouped into Thl  and Th2 cytokines 
with the former including IL-2 and IFNy and the latter 
IL-4 and IL-5 (Mosmann and Sad, 1996). The Thl  and 
Th2 cytokines usually dictate a different pattern of tissue 
immune-inflammatory responses. Certain cytokines that 
are not exclusively released by lymphocytes but are 
involved in Th cell differentiation or Thl  or Th2 tissue 
responses, may also be categorized into Thl  or Th2-type 
cytokines. The use of animal models has remarkably 
helped dissect the role of cytokines in pulmonary 
inflammatory or immune diseases. One important 
advantage of using the mouse rather than other species is 
the unique accessibility to many immunologic reagents 
including gene knock-out mouse strains. However, it is 
also important to bear in mind that there are certain 
differences in respiratory anatomy and histology 
between ourselves and rodents. For instance, the left 
lung of rodents consists of only one lobe and the right 
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lung is divided into the apical, middle, posterior and a 
small accessory lobe (Boorman and Eustis, 1990). 
Histologically, rodent airways do not have well- 
developed respiratory bronchioles and, from the lower 
portion of trachea there is no submucosal glands. Of 
prominence, in contrast to those in humans, the 
conducting airways lack the submucosal layer, 
comprising only the epithelia1 and fibrous subepithelial 
connective tissue layers.  While examinations of 
cytology, morphology, gene expression and protein 
levels in models established in normal adult rodents still 
remain important and useful, the "loss of function" or 
"gain of function7' approaches by genetic engineering 
have revolutionized the way by which we study the 
function of cells or cytokines of interest. In this regard, 
many pulmonary diseases can now be studied in a mouse 
strain defective in a given immune cell type or cytokine, 
or in a mouse strain overexpressing a cytokine (Ho, 
1994). Discoveries from such studies have remarkably 
helped us unravel the previously unknown cause of 
certain human ailments. For instance, mice deficient in 
IFN-y were found to succumb to systemic or pulmonary 
tuberculous infection (Cooper et al., 1993), and this 
experimental finding has recently led to the finding 
that a certain number of children who developed 
disseminated tuberculous infection following vaccina- 
tion with Mycobacterium bovis BCG or who were 
susceptible to infections caused by opportunistic myco- 
bacteria, carried a genetic defect in the ligand binding 
subunit of IFN-y receptor (Jouanguy et al., 1996; 
Newport et al., 1996). Mice deficient in GM-CSF 
suffered a pulmonary disease called pulmonary alveolar 
proteinosis (Dranoff et al., 1994) and this finding has 
recently led to identification of a mutation in the gene 
coding for the common l3 chain of receptors for GM- 
CSFIIL-3lIL-5, in patients with pulmonary alveolar 
proteinosis (Dirksen et al., 1997). Findings of such 
nature will undoubtedly foster the determination of 
relative genetic propensity to certain diseases and the 
development of new therapeutic strategies. 
Cytokines in experimental models of endotoxic lung 
The alveolar macrophage resides both in the alveolar 
and interstitial spaces, serving as part of the innate 
defense mechanism in the lung. Normally, this cell type 
outnumbers the lymphocyte in the lung with a ratio 5-10 
to 1. In situations in which the number of invading 
microorganisms exceeds the capacity of primary defense 
mechanisms, neutrophils (PMN) are called in in 
response to microbial-derived products, complement, 
leukotrienes and chemokines, thus operating as  a 
powerful back-up defense mechanism during acute 
pulmonary infection (Stockley, 1995). Such neutrophilic 
accumulation in the lung is a pathologic hallmark of 
acute lung inflammation. Since the Gram-negative 
bacterium represents a frequent pathogen causing 
pneumonia through either a direct local or systemic 
route, Gram-negative bacterium-derived lipopoly- 
saccharide (LPS) is commonly used to elicit an acute 
neutrophilic inflammatory response in the lung to study 
the molecular mechanisms (Friedland and Griffin, 1992; 
Manthey and Vogel, 1992). Routinely, LPS is intra- 
tracheally (it.) instilled into rat or mouse lung. We have 
also developed a mouse model of acute lung 
inflammation by delivering aerosolized LPS in a 
Plexiglas chamber (Xing et al., 1998). This technique 
simplifies the procedure of delivery and avoids potential 
homeostatic alterations induced by surgical trauma 
during i.t. procedure. LPS triggers a quick neutrophil 
response in the lung which can be appreciated 
microscopically within the pulmonary vasculature and in 
the insterstitium at as early as 0.5-lh post-challenge. 
Significant accumulation of PMN in bronchoalveolar 
lavage fluid (BAL) was noticed by 3h, peaked at 12 to 
24h and declined to background levels by 72h (Xing et 
al., 1993, 1998). There was also an increase in the 
number of alveolar macrophages (Xing et al., 1993; 
Shellito et al., 1995). These kinetics of PMN trafficking 
mimic the course of acute pneumonia in humans, thus 
providing an opportunity to study the role of cytokines 
in the pathogenesis of acute pneumonia. Expression in 
lung tissue of mRNAs for both TNFa and MIP-2 was 
quickly turned on by lh,  followed by IL-1B and IL-6 
(Xing et al., 1994). I t  is quite likely that the onset of 
TNFa expression preceded MIP-2 if such examination 
was carried out at earlier time points. At cytokine protein 
levels, the release of TNFa, MIP-2 and IL-6 peaked at 
about 4h and markedly declined by 72h. Thus, the 
cascade of cytokines TNFa, MIP-2 and IL-6 is part of 
important mechanisms orchestrating the host response to 
such nonimmune stressors as LPS. In addition to direct 
induction of MIP-2 and IL-6 by LPS, T N F a  may 
amplify such induction (Fig. 1). 
TNFa is a well-known pro-inflammatory cytokine 
capable of multiple functional activities including 
inducing cytokine release from many cell types and 
enhancing the adhesion of PMN to the endothelium by 
upregulating cell surface molecules intercellular 
adhesion molecule 1 (ICAM-l) and CDlla/CD18 on the 
endothelium and PMN, respectively. MIP-2, like KC, is 
a member of the C-X-C chemokine family with potent 
chemotactic activity for rodent PMN both in vitro and in 
vivo (Huang et al., 1992; Strieter et al., 1993; Gupta et 
al., 1996; Foley et al., 1996). An anti-MIP-2 antibody 
reduced, but not completely inhibited, lung neutrophilia 
by LPS, suggesting an important role for this chemokine 
and the participation of additional chemotactic factors in 
the full-blown lung neutrophilia (Schmal et al., 1996). 
The issue regarding the role of IL-6 during acute 
neutrophilic inflammation in the lung is of fundamental 
importance. IL-6 is clearly a critical cytokine which 
together with T N F a  and IL- l ,  induces acute phase 
reactions comprising fever, hepatic release of acute 
phase proteins and adrenal corticosteroid release, during 
almost any alarm responses including acute pulmonary 
infections (Baumann and Gauldie, 1994). In this regard, 
IL-6 is expressed at the tissue site of inflammation and 
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released into the circulation whereby IL-6 operates as an 
exocrine hormone-like molecule (Gauldie et al., 1990). 
The functional role of IL-6 in the lung during acute 
inflammation had remained an unsolved issue until our 
recent studies by using mice deficient in IL-6 (Xing et 
al., 1998). We demonstrate that endogenous IL-6 in the 
lung is an antiinflammatory cytokine functioning to 
control the level of proinflammatory cytokines TNFa 
and MIP-2 and subsequently the level of lung 
neutrophilia and that such functions of IL-6 cannot be 
compensated for by other members of the IL-6 cytokine 
family (Kishimoto et al., 1992). Of interest, IL-6 appears 
to have little effect on the duration of neutrophilic 
inflammation since like in the wild-type mice, lung 
neutrophilia largely subsided by 72h in IL-6-deficient 
mice (Xing et al., 1998). This finding does not support a 
role of IL-6 in enhancing PMN apoptosis as suggested 
from a previous in vitro observation (Afford et al., 
1992). Exogenously administered recombinant IL-6 has 
been shown to attenuate LPS-induced lung neutrophilia 
(Ulich et al., 1991a). Among other antiinflammatory 
cytokines that are likely involved in controlling acute 
lung inflammation are IL-10 and IL-1 receptor 
antagonist protein (IRAP). IL-10 is a well recognized 
antiinflammatory cytokine (de Vries, 1995). Interesting- 
ly, in contrast to marked induction by LPS of IL-6 
locally in the lung, we found that a low constitutive level 
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Fig. 1. Overview of cytokine actions and cellular sources during 
endotoxin-induced acute pulmonary inflammation. Endotoxin activates 
alveolar rnacrophages to release cytokines including TNFa, MIP-2, IL-l 
and IL-6. Neutrophils are then recruited into the lung in response to both 
endotoxin and macrophage-derived cytokines and become an active 
source of these cytokines themselves at the time when expression level 
in rnacrophages wanes. All of these cytokines act in an autocrine and 
paracrine fashion. In contrast to TNFa, MIP-2 and IL-l, IL-6 operates as 
an antiinflammatory cytokine during acute pulmonary inflammation. 
of IL-10 was not enhanced by LPS (Xing et al., 1998), 
suggesting that this cytokine plays a relatively less 
important role in controlling acute lung inflammation. 
However, whether this is also the case in humans 
remains to be determined. Local exposure to LPS also 
induced IRAP expression and i.t. administration of 
recombinant IRAP attenuated LPS-induced neutrophilia 
(Ulich et al., 1991b, 1992). 
The cellular sources of cytokines during acute lung 
inflammation have been an interesting topic of research. 
In a rat model of LPS-induced acute lung inflammation, 
we dissected the cellular sources of cytokines by using 
Northern hybridization with total cellular RNA from 
purified alveolar macrophages (AM) and PMN, 
immunohistochemistry, and in situ hybridization. We 
found that AM represented an early source of pro- 
inflammatory cytokines which may not be of total 
surprise since these cells are the first line of defense in 
the deep airways. These cells expressed remarkable 
messages for TNFa, MIP-2, IL-113 and IL-6 by l h  post- 
LPS challenge which declined markedly between 6 and 
12h (Xing et al., 1994). Interestingly, at these later times 
when cytokine expression waned in AM and neutrophil 
infiltration started to be prominent, PMN became a 
striking source for all of these cytokines expression of 
which peaked at 6h and remained still significant by 12h. 
These findings by Northern hybridization were verified 
in the lung by immunohistochemistry and in situ 
hybridization (Xing et al., 1993, 1994). These studies 
have provided the first experimental evidence that AM 
and PMN account for temporal waves of cytokine 
expression during the course of acute lung inflammation, 
and that cytokines from AM may be important in 
triggering PMN trafficking and activation whereas those 
from PMN contribute to the amplification of responses 
and the autoactivation of PMN (Fig. 1). 
Whether rodent models of endotoxic lung represent 
ideal models of acute lung injury remains a contentious 
issue. Such models are not models of adult respiratory 
distress syndrome (ARDS). Apparently, pathologies seen 
in LPS models lack the two essential components 
characteristic of ARDS: severe alveolar epithelia1 
damage and fibrotic reaction (Bachofen and Weibel, 
1977). Unfortunately, a real straightforward model of 
ARDS is not yet in immediate reach, which restricts 
investigations into the mechanisms by which the disease 
progresses into the stage of fibrosis. During LPS- 
induced acute inflammation, the lack of severe lung 
injury boils down to the issue regarding whether PMN 
are fully activated. From cytokine expression point of 
view, LPS, perhap together with AM-derived cytokines, 
indeed activates PMN to express a wide array of 
cytokines. However, whether these granulocytes undergo 
degranulation to release proteases such as elastase is 
unclear. It appears that i t  is difficult to demonstrate 
elastase activities in BAL fluids from rodent lungs 
(Delclaux et al., 1997) while increased elastase activities 
have been demonstrated in BAL from guinea pig lungs 
post-LPS challenge (Sakamaki et al., 1996). Never- 
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theless, these drawbacks should not detract these models 
from studies aiming to dissect the role of cytokines and 
other soluble mediators and adhesion molecules in the 
development and resolution of acute lung inflammation. 
Indeed, the rodent models of LPS-induced acute 
lung inflammation with a self-limiting nature have 
proven useful for studies looking into the mechanisms 
underpinning the resolution of inflammation. It has been 
generally believed, primarily based upon in vitro 
observations that one major mechanism by which acute 
neutrophilic inflammation undergoes an effective 
clearance is apoptosis and subsequent engulfment by 
macrophages of apoptotic PMN (Savill et al., 1993). We 
have demonstrated a close correlation between the 
resolution of neutrophilic accumulation and the 
appearance and the subsequent macrophage engulfment, 
of apoptotic PMN during the course of acute lung 
inflammation (Cox et al., 1995). These latter two events 
were found slightly lagged behind the peak neutrophilic 
response to i.t. challenge with LPS, suggesting that such 
mechanisms play a critical role and are amazingly 
efficient in clearing massive neutrophilic accumulation 
in the lung. 
Cytokines in experimental models of endotoxemia 
The acute neutrophilic inflammatory response is also 
often a local presentation in the lung during endotoxemia 
caused by Gram-negative infections that did not 
originate in the lung. In this case, the response results 
from exposure to endotoxin and cytokines in the blood- 
stream. Different from acute lung inflammation elicited 
by local endotoxin exposure during which there is 
primarily a compartmentalized cytokine response within 
the lung and an intraalveolar neutrophilic accumulation 
(Nelson et al., 1989), there is, during endotoxemia, an 
initial drop in the number of peripheral blood PMN and 
lymphocytes (Terebuh et al., 1992), and a large number 
of PMN becomes sequestered within the pulmonary 
vasculature with relatively few infiltrating the alveolar 
space (Nelson et al., 1989). Moreover, there is a swift 
cytokine surge in the bloodstream upon the onset of 
endotoxemia (Nelson et al., 1989; Manthey and Vogel, 
1992). It was often observed that during endotoxemia, 
circulating TNFa level peaked earliest around l h  post- 
systemic LPS challenge (Manthey and Vogel, 1992). We 
recently observed that levels of MIP-2 and IL-10 also 
rapidly rose to a peak around the same time as TNFa 
during endotoxemia (Xing et al., 1998). These first 
waves of cytokines were followed by IL-6, GM-CSF and 
IFNy which peaked at about 3h, 3h and 6h, respectively 
(Chensue et al., 1991; Tiegs et al., 1994; Xing et al., 
1998). By examining mRNA expression for TNFa or 
IL-6, we investigated the potential contribution of 
various tissue sites to the circulating level of cytokines 
during endotoxemia. Among all organs analyzed, 
spleen/lung/heart and spleen/lung/heart/muscle are the 
major sites for TNFa and IL-6 expression, respectively 
(Xing et al., 1997a). It is clear that TNF-y, MIP-2, GM- 
CSF and IFNa all contribute to the development of toxic 
syndromes and multiorgan injuries during endotoxemia 
(Tiegs et al., 1994; Standiford et al., 1995; Schmal et al., 
1996; Bundschuh et al., 1997). The critical role for 
TNFa has been demonstrated not only by using an anti- 
TNFa antibody (Remick et al., 1990) but also by using a 
transgene-derived TNFa-antagonizing soluble TNFa 
receptor (Rogy et al., 1995). In addition, IL-la but not 
IL-113 may also be a critical player since mice deficient 
in both IL- la  and IL-113 (ICE-deficient mice) but not 
mice only deficient in IL-113 were protected from lethal 
challenge of LPS (Gutierrez-Ramos and Bluethmann, 
1997). Of special interest, in contrast to little induction 
of IL-l0 release in the lung post-LPS aerosol exposure 
(Xing et al., 1998), the circulatory level of IL-10 
markedly increased during endotoxemia, suggesting an 
important role of this potent antiinflammatory cytokine. 
Indeed, neutralization of IL-10 increased lethality of 
mice in endotoxemia (Standiford et al., 1995) and 
administration of recombinant IL-10 or a plasmid DNA 
containing IL-10 transgene protected mice from lethal 
endotoxemia (Howard et al., 1993; Rogy et al., 1995). 
Recently, we have demonstrated inhibited cytokine 
production during endotoxemia by using adenoviral- 
mediated intramuscular IL-10 gene transfer (Xing et al., 
1997a). The role of IL-6 in endotoxemia, in addition to 
its effect on the induction of acute phase reactions, has 
been a matter of debate, owing to conflicting 
experimental results obtained by using monoclonal 
antibodies against IL-6. Adequately addressing this issue 
is of fundamental importance. IL-6 is induced and 
released into circulation in almost all of alarm situations 
including trauma and acute infections and the circulating 
level of this cytokine is closely correlated with mortality 
(Zitnik and Elias, 1993). However, this correlation 
cannot provide a causal relationship since heightened IL- 
6 levels could be part of host attempt in trying to restore 
homeostasis, directly related to the extent of tissue 
injury. To address the role of endogenous IL-6, 
monoclonal antibodies against IL-6 were used in models 
of endotoxemia but the results are confusing, supportive 
of either a protective or detrimental role of IL-6 (Starnes 
et al., 1990; Heremans et al., 1992; Barton et al., 1993). 
Now it has become clear that anti-IL-6 monoclonal 
antibodies, instead of neutralizing IL-6 activities, 
chaperone circulating IL-6 by binding to this molecule to 
prolong its half-time and biologic activities (Heremans 
et al., 1992; May et al., 1993). To this end, we have 
investigated the cytokine profile and mortality in IL-6 
gene knock-out (IL-6-1-1 mice during endotoxemia (Xing 
et al., 1998). We found that in the absence of IL-6, levels 
of proinflammatory cytokines including TNFa, MIP-2, 
GM-CSF and IFNy were many times those in wild type 
mice while the level of antiinflammatory IL-l0 remained 
similarly increased in both IL-~- / -  and IL-6+/+ mice. In 
addition, there was an increased mortality in IL-6-1- post- 
lethal i.p. challenge of LPS. These findings provide 
crucial evidence pointing to the antiinflammatory nature 
of IL-6 during endotoxemia by controlling the level of 
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proinflammatory, but not antiinflammatory, cytokines. In 
this respect, i t  is apparent that IL-10 per se and other 
members of the IL-6 cytokine family are not sufficient to 
compensate for the function of IL-6. Thus,  the 
antiinflammatory activities of IL-6 in both local lung and 
systemic acute inflammatory responses are in keeping 
with other antiinflammatory aspects of this cytokine 
including induction of IRAP and TNFsR and protease 
inhibitors (Lotz and Guerne, 1991; Tilg et al., 1994). It is 
worth mentioning, however, that different from the role 
of IL-6 in acute inflammatory responses, IL-6 appears to 
enhance, instead of dampening, specific immune 
responses against chronic intracellular infections and 
tumor (Xing et al., 1998). In addition to IL-10 and 
IL-6, MCP-1 has recently been found to have anti- 
inflammatory properties in endotoxemia (Zisman et al., 
1997a). 
While the protective effect of anti-cytokine regimens 
may be attained in rodent models of endotoxemia, 
clinical trials using anti-TNFa or IRAP have not yielded 
consistent results (Bernard, 1995). The debate continues 
with regard to whether it is beneficial to dampen pro- 
inflammatory cytokines which are paradoxically 
important in fighting against the causative Gram- 
negative infectious agents. Recently, there has been 
emerging evidence supporting a protective role of certain 
pro-inflammatory cytokines in host resistance to 
systemic Gram-negative infections. Anti-IL-12 therapy 
was found to protect mice during lethal endotoxemia but 
impair bacterial clearance during E. coli induced 
peritonea1 sepsis (Zisman et al., 1997b), and MCP-1 
protected mice from systemic infection with Pseudo- 
rnorras aeruginosa or Salmonella lyphimurium. These 
suggest the relevance of using models of Gram-negative 
infections rather than models of LPS-induced endo- 
toxemia to testing the efficacy of therapeutics such as 
recombinant or transgene-derived cytokine antagonists. 
Cytokines in experimental models of acute 
pulmonary infections caused by Gram-negative 
bacteria 
The morbidity and mortality of acute bacterial 
pneumonia have been increasing world-wide. Acute 
pneumonia is the leading cause of death of all 
nosocomial infections (Standiford and Huffnagle, 1997). 
Among the most frequent causative bacteria are Gram- 
negative E. coli and Pseudornonas aeruginosa. With 
increased mortality and emergence of drug-resistant 
strains of bacteria, there is an urgent need to understand 
host defense mechanisms in order to develop better 
prophylactic and therapeutic strategies. From this 
viewpoint, animal models of acute pulmonary infections 
are certainly superior to those elicited by LPS. 
Apparently, pathologic changes seen in acute lung 
inflammatory responses induced by LPS alone or by 
Gram-negative bacteria in rodent models are not 
identical. In a side-by-side comparison study, i t  was 
found that compared to pathologies induced by i.t. LPS, 
Pseudomonas aeruginosa induced a more pronounced 
lung injury marked by greater degrees of hemorrahage 
and proteinous exudation although the intensity of 
neutrophilia, albeit somewhat delayed, was similar to 
that by LPS (Delclaux et al., 1997). Such differences are 
likely accounted for by bacterial virulent factors in 
addition to LPS. Therefore, cautions should be taken 
when extrapolation is being made from the data obtained 
in models of endotoxic lung. It is generally believed that 
the innate immune components including alveolar 
macrophages, neutrophils and NK cells play a critical 
role in the primary pulmonary bacterial infection, 
whereas the acquired specific cellular and humoral 
immune responses play a critical role in host defense 
against the secondary infection. The role of T cells in 
host resistance to primary acute pulmonary bacterial 
infections remains unclear. Increased T cells were 
noticed at later stages of acute lung inflammation 
elicited by LPS but these cells were not involved in 
PMN clearance (Morris et al. ,  1997). And T cell 
accumulation and T cell-mediated host responses in 
primary, particularly chronic Pseudomonas-induced 
pneumonia have been reported (Stevenson et al., 1995; 
Wiebke et al., 1995). It should be noted that likely, there 
are no true primary infections in humans since most 
Gram-negative bacteria with pathogenic potentials 
colonize the upper respiratory, intestinal and lower 
urogenital tracts and quite some of us may have had 
subclinical local or systemic infections prior to the first 
clinical episode of pneumonia, and that host responses 
during chronic pulmonary pneumonia may differ from 
those involved in an acute episode. From this point of 
view, appropriate animal models of primary pulmonary 
infection must be accordingly developed to address the 
role of various cell types and cytokines involved in both 
innate and acquired immune-inflammatory responses. 
Mouse models of chronic pneumonia caused by Pseudo- 
monas aeruginosa have been developed to study host 
responses against such chronic infections frequently seen 
in patients with cystic fibrosis. I t  is of interest that lung 
cellular responses and in vitro T cell responses appear 
different between various strains of mice with C57BLJ6 
and BalbJc mice being susceptible and resistant, 
respectively (Morissette et al., 1995; Stevenson et al., 
1995). 
Although certain cytokines have been analyzed at 
mRNA levels in these models to address the potential 
mechanisms underlying such strain differences and 
TNFa seems expressed at a higher level in the lung of 
resistant Balblc mice (Gosselin et al., 1995), it remains 
to be determined whether immune-modulatory cytokines 
are involved at protein levels. By using a mouse model 
of acute bacterial pneumonia elicited by i.t. inoculation 
of virulent Klebsiella pneumoniae, it was found that 
accumulation of PMN and AM peaked around 48 h post- 
infection (Standiford et al., 1996). These peak cellular 
responses appeared correlated with peak production in 
lung homogenates of pro-inflammatory cytokines IL-12, 
T N F a ,  MIP-2 and M I P - l a  and antiinflammatory 
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cytokine IL-10 (Greenberger et a l . ,  1995,  1996;  
Standiford et al., 1996). Such cytokine kinetics are 
apparently much delayed compared to those elicited by 
i.t. LPS challenge (Xing et al., 1994), perhaps due to the 
fact that small inocula of bacteria required a certain 
period of time to replicate within the lung. IL-12, TNFa 
and MIP-2 have each been shown to be required for host 
resistance to Klebsiella infection (Standiford et al., 1995; 
Greenberger et al., 1996; Laichalk et al., 1996) or 
Pseudornonas aeruginosa infection in the lung (Kolls et 
al., 1995). Local lung induction of IL-10 by bacterial 
infection is in contrast to our recent finding that little IL- 
10 was induced during acute lung inflammation by LPS 
(Xing et al., 1998). Interestingly, neutralization of this 
endogenous IL-10 decreased the mortality of mice which 
was accompanied with increased levels of TNFa, MIP-2 
and MIP-la, and decreased bacterial counts in the lung 
and peripheral blood (Greenberger et al. ,  1996), 
suggesting a critical role of these cytokines in host 
defense. The relative contribution of these cytokines and 
their cellular sources remain to be elucidated. TNFa, IL- 
la and IL-6 were also induced in the lung during acute 
pulmonary infection by Gram-positive Sfreptococcus 
pneumoniae (Bergeron et al., 1998). Little is known 
about the role of IFNy and GM-CSF during acute 
pulmonary infections by extracellular Gram-negative 
bacteria. The critical role of IFNy in host defense against 
acute lung infection by Gram-positive Streptococcus 
pneumoniae has recently been demonstrated in IFNy -1- 
mice but interestingly, this cytokine was induced only in 
the peripheral blood but not in the lung of wild type 
mice (Rubins and Pomeroy, 1997). GM-CSF has been 
shown to be induced during LPS-induced lung neutro- 
philia (Huffman Reed et al., 1997). While chemokines 
MIP-2 and MIP- la  have been shown to increase the 
bactericidal activities of PMN and AM in v i tro  
(Standiford et al., 1996), it remains to be fully under- 
stood how these proinflammatory cytokines contribute to 
host responses in the lung. 
Thus, these findings support an emerging notion that 
proinflammatory cytokines are required for effective 
host defense mechanisms against acute pulmonary 
bacterial infection. This notion has prompted a number 
of preclinical and clinical trials in which a selected 
proinflammatory cytokine is overexpressed locally or 
systemically by transgene approaches or administering 
recombinant proteins to boost innate immune responses 
(Standiford and Huffnagle, 1997).  The  local i . t .  
administration of a replication-deficient adenoviral 
vector expression IL-12 decreased the mortality of mice 
with Klebsiella pneumonia (Greenberger et al., 1996). 
By using similar techniques, IFNy expression was found 
to aid in the clearance from the lung of Pseudomonas 
aeruginosa in mice (Kolls et al., 1997). Currently, we 
are investigating the role of cytokines and the potential 
application of adenoviral vectors expressing pro- 
inflammatory cytokines in models of pulmonary 
infections by Pseudornonas aeruginosa or E. coli. I t  is 
important to realize that these experimentations are still 
in their infancy. Further understanding is required about 
the relative contribution of each cytokine involved in 
order to decide which cytokine should be used for 
immunotherapy as an adjuvant to chemotherapy, and this 
should be explored in the context of a given pulmonary 
bacterial infection since the protective immune- 
inflammatory response to each infection may not involve 
identical immune-modulatory molecules. Furthermore, 
different techniques and routes of administration must be 
explored to deal with the confounding issue that it is the 
circulating proinflammatory cytokines that cause 
endotoxic syndromes often seen in patients with Gram- 
negative infection-associated endotoxemia. 
Cytokines in experimental models of chronic 
pulmonary infections caused by intracellular 
bacteria 
The most common intracellular bacteria that cause 
chronic pulmonary infections are mycobacteria, 
particularly Mycobacterium tuberculosis (MT). The 
mycobacterium is an obligate intracellular pathogen of 
macrophages. Pulmonary tuberculous infection (TB) 
accounts for increasing morbidity and morbility across 
the world. Approximately eight millions of new TB 
cases emerge and three millions of people die of this 
disease every year. The socioeconomic changes, the 
ineffectiveness of BCG vaccine and the spread of drug 
resistant strains of MT, particularly in patients with HIV 
infection have all contributed to increased incidence and 
mortality (Cooper and Flynn, 1995). Ironically, 
relatively little is known about the nature of protective 
immune-inflammatory responses. The Th l  cytokines 
including IL-12, IFNy and TNFa are believed to play a 
determining role in the development of immune- 
inflammatory responses against pulmonary TB (Munk 
and Emoto, 1995). Animal models, particularly those 
established in mice, are  instrumental to helping 
understand the mechanisms of disease including the role 
of cytokines. The majority of studies have been carried 
out by i.v. administration of virulent MT or attenuated 
live M. bovis BCG. Since T B  is primarily a respiratory 
disease and recent evidence indicates that the pattern of 
responses in the lung may differ from that at other tissue 
sites (Medina and North, 1996), increasing efforts are 
being made to establish mouse models of pulmonary TB 
elicited by airway inoculation of mycobacteria. Indeed, 
if the same cfu of MT that lodged in the lung following 
i.v. infection were aerosolized into the lung, the 
pathological sequela were different. Airway inoculation 
elicited a faster and greater development of lung 
pathology characterized by mononuclear cell accumula- 
tion, alveolar injuries and interstitial fibrotic reactions 
(North, 1995). And these mice succumbed to such 
infection much sooner than mice infected via a systemic 
route. In addition, compared to other organs, lung is the 
only organ that allows progressive replication of MT 
regardless of the route of inoculation (North, 1995), 
suggesting differential immune-inflammatory mecha- 
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nisms involved in controlling mycobacterial infection in 
the lung. Mouse models of pulmonary tuberculous 
infection may be ideally set up by aerosolization of 
virulent MT, a process mimicking aerobic mycobacterial 
infection in humans (North, 1995). The experimental 
duration is lengthy with such models and the majority of 
immune-competent mice do not succumb to infection 
until about 120 days post-infection. Alternatively, i.t. 
administration may be carried out to deliver larger doses 
of mycobacteria and this approach seems to shorten the 
duration of experiments and elicits pathologic processes 
similar to those by aerosol infection (Hernhndez-Pando 
et al., 1996). The models elicited by virulent strains of 
mycobacteria are more relevant to human diseases but 
the requirement of higher levels of biohazard 
containment facility poses restrictions to carrying out 
detailed dissections of cellular and molecular events. On 
the other hand, while the models established with 
attenuated strains allow such studies, they are not ideal 
models for studying certain aspects of TB as well as the 
efficacy of therapeutic agents. 
We have developed a mouse model of pulmonary 
tuberculous infection by i.t. administration of attenuated 
live M. bovis BCG. In immune-competent C57BLl6 
mice, BCG elicited an early granuloma formation in the 
peribronchial and perivascular areas between days 7 and 
14 and such granulomatous responses became culminant 
by day 27, involving large areas of lung parenchyma and 
consisting of macrophages, epithelioid cells, Iympho- 
cytes and neutrophils as well as hyperplastic type I1 
epithelia1 cells (Wakeham et al., 1998). Different from 
pathologies in humans, there was a lack of giant 
multinuclear cells. The degree of lung structural damage 
was less than that by virulent mycobacteria. Of note, 
such pulmonary inflammatory responses were self- 
limiting in nature in immune-competent mice which by 
days 57  and 71 started to decline leaving only mild 
degrees of foamy macrophage accumulation. The 
resolution of responses was in accordance with 
decreasing numbers of bacilli detected in lung tissue at 
later time points. The effective control of mycobacterial 
infection in the lung was mirrored by minimal systemic 
dissemination of bacilli to the spleen. We have analyzed 
in detail the cytokines that are involved in immune- 
inflammatory responses in the lung. We found that the 
protein levels of Thl cytokines IL-12, IFNy and TNFu 
were not markedly induced in the lung until day 14, 
became maximal by day 27, markedly declined by day 
57, suggesting that specific cellular immune responses 
were required for such optimal cytokine responses and 
these cytokines contributed to vigorious tissue 
inflammatory responses. By FACS analysis, in addition 
to increased pulmonary macrophages and NK cells, the 
majority of T cells were found to be CD4 T cells, 
pointing to the importance of this T cell subset. Of 
interest, there was little induction of a Th2 cytokine IL-4 
throughout the entire course of our study, 71 days, 
suggesting a little role of Th2  cytokines during 
pulmonary mycobacterial infection. The lack of IL-4 
response in the lung was also confirmed by in vitro 
antigen stimulation assay using total lung mononuclear 
cells (Wakeham et al., 1998). We found a lack of Th2 
cytokines in both C57BLl6 and Balblc strains of mice, 
which does not support the previous in vitro 
observations that IL-4 may play a role at later stages of 
immune responses against mycobacterial infection 
(Huygen et al., 1992; Orme et al., 1993). Neither was a 
Th2 cytokine response found in human tuberculosis (Lin 
et al., 1996). Instead, a weakened Thl  cytokine response 
caused by a genetic defect or immune suppressive 
infections may be the etiology of increased susceptibility 
of certain populations to tuberculous infections 
(Jouanguy et al., 1996; Newport et al., 1996). To address 
the relative role of IL-12 in the development of 
protective host responses during pulmonary myco- 
bacterial infection, we carried out studies using mice 
deficient in IL-12. In the absence of functional IL-12, 
mice demonstrated a defect in mounting granulomatous 
responses in the lung with minimal formation of atypical 
granulomas comprising primarily lymphocytes through- 
out 71 days. BAL cellular analysis revealed a decrease 
not only in the number of macrophages but lymphocytes 
and neutrophils. These led to uncontrolled replication of 
bacilli in the lung and systemic dissemination. On FACS 
analysis, there was a lack of CD4 and CD8 T cell 
responses. Not only was there a defect in such primar 
immune-inflammatory responses in the lung of IL-12- 1 
mice, but also a defect in memory immune responses as 
shown by a lack of IFNy recall response in antigen- 
stimulated purified lung mononuclear cells.  The  
underlying molecular mechanisms were found to be a 
complete lack of IFNy and a severely impaired TNFu 
response both in the lung and peripheral blood 
(Wakeham et al., 1998). And to our surprise, such a lack 
of Thl  cytokines did not favor a shift to a Th2 cytokine 
response since the level of IL-4 protein remained similar 
to that in immune-competent mice. Our findings lend 
support to a recent report that IL-4 was not induced in 
the liver following i.v. infection with MT in IL-12-1- 
mice (Cooper et al., 1997). Together, these findings do 
not seem to support the theory of reciprocal inhibition of 
expression between Thl  and Th2 cytokines, at least in 
the context of mycobacterial infection (Mosmann and 
Sad,  1996). It is possible that the in vivo T cell  
differentiation process is regulated in a far more 
complicated fashion and that certain soluble signals 
required for Th2 cell differentiation may be.missing in 
the absence of IL-12 and other down-stream cytokines 
IFNy and TNFa. However, in a model of intracellular 
parasitic infection, leishmaniasis, the lack of IL-12 
polarized a Th2 cytokine response (Mattner et al., 1996). 
Furthermore, i t  is well known that the type of Th 
responses depends on the MHC genetic background 
during leishmaniasis with a T h l  or a Th2 phenotype 
developed in C57BLl6 and Balblc mice, respectively. 
But an antigen ovalbumin elicited a typical Th2 airways 
response in both C57BLl6 and Balblc mice (Stampfli et 
al., 1998). These findings thus suggest that the initial 
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cytokine microenvironment determined by the nature of 
eliciting agents upon the interaction with antigen- 
presenting cells and NK cells, and the differential 
expansion of T cell progenitors determined by antigenic 
epitopes presented specific to each MHC haplotype, may 
all dictate the type of Th responses. 
IL-12-1- mice have also recently been employed to 
examine the role of IL-12 in host defense during 
systemic mycobacterial infection elicited by MT 
(Cooper et al., 1997). The lack of this cytokine led to 
much delayed mRNA expression of IFNy and TNFa in 
the liver and uncontrolled mycobacterial replication in 
various organs. The rebounded expression of IFNy and 
T N F a  in the liver at later stages of infection is of 
particular interest which is in contrast to our findings 
that there is a lack of these cytokines throughout the 
entire course of pulmonary mycobacterial infection, 
suggesting the lack of potential compensatory mecha- 
nisms in the lung. One mechanism could be linked to IL- 
18  which has recently been shown to have certain 
redundant functions and synergistic activities with IL-12 
(Lamont and Adorini, 1996; Kohno et al., 1997). Indeed, 
in the study by Cooper et al., high levels of IL-18 
mRNA were found in the liver but i t  remains unclear 
whether there was a correlation between IL-18 induction 
and the rebound of IFNy and T N F a  expression. 
Examining IL-l8 at the protein level and using specific 
IL-18 abrogating antibodies shall help clarify the role of 
IL-18 in this model. It would be 01 ~nterest  to also 
examine IL-18 expression at various tissue sites during 
. pulmonary mycobacterial infection. Apparently, 
identification in molecular terms of the difference in 
immune-inflammatory responses between the lung and 
liver/spleen will help understand why the lung but not 
other tissues allows the progressive growth of MT 
(North, 1995). From all of these findings, it is plausible 
to consider IL-12 as an upstream molecule required for 
the elicitation of effective cellular immune-inflammatory 
responses during pulmonary mycobacterial infection. 
The downstream events include the differentiation and 
expansion of Thl  cells and CD8 T cells, the release of 
IFNy from T and NK cel ls  and the activation of 
pulmonary macrophages (Fig. 2). IL-12 appears required 
for a full T N F a  response as well but whether an 
impaired TNFa response that we observed was a result 
of the lack of IL-12 or IFNy remains to be fully 
understood. It is possible that in our model TNFa  is 
primarily released from pulmonary macrophages but not 
lymphocytes. While IFNy may activate macrophages to 
release TNFa, recent evidence has also suggested that 
IL-12 may induce a TNFa response independent of IFNy 
(Taylor and Murray, 1997), and that IL-12 can directly 
act upon macrophages (Puddu et al., 1997). Thus, IL-12 
may play a much broader role than IFNy in immune- 
inflammatory responses during pulmonary myco- 
bacterial infection, despite that mice deficient for IFNy 
or TNFa  or TNFa  receptor are more susceptible to 
systemic or local lung infection by MT or M. bovis BCG 
(Kindler et al., 1989; Flynn et al., 1993, 1995). In 
consistence with the role of IL-6 in the amplification of 
specific immune responses, mice deficient in IL-6 were 
found to succumb to inoculation of MT at doses that 
were sublethal to w.t. mice (Ladel et al., 1997). 
Understanding the cellular and molecular events and 
the nature of key cytokines involved in protective host 
responses will certainly help design better vaccines 
including recombinant cDNA vaccines (Huygen et al., 
1996) and foster the notion of immunotherapy for TB 
patients, particularly those with drug-resistant TB. 
Recombinant viral or cDNA vaccines can be potentially 
engineered to CO-express immunogenic antigens and 
immunomodulatory cytokines. These vaccines may 
enhance immunization efficacy in hosts who fail to 
mount adequate immune memory responses to 
conventional TB vaccines due to different MHC genetic 
background. Aerosol delivery of recombinant IFNy has 
been tested on TB patients and some efficacy noticed 
(Condos et al., 1997). Cytokine gene therapy represents 
an economical and efficient way to boost immune 
responses and has the potential to be used to 
complement the current chemotherapy. However, what 
to express, which type of gene transfer vectors to use 
and how to deliver the transgene will entail rigorous 
experimental explorations ahead. Since tuberculous 
infection primarily originates in the lung and i t  assumes 
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Fig. 2. Putative role of Thl  cytokines in host defense against pulmonary 
mycobacterial infection. Interaction of mycobacteria with macrophages 
releases IL-12 which plays an important role in induction of IFNy by NK 
and T lymphocytes and T h l  phenotype differentiation. Activated 
antigen-specific T cells undergo proliferation and become cytotoxic. 
N W  cell-derived lFNy and perhaps macrophage-derived 11-12 both are 
required for full activation of macrophages, leading to enhanced release 
of TNFa, lFNy and IL-12 by macrophages and increased myco- 
bactericidal activities. 
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a chronic course, a prolonged cytokine gene expression 
locally in the lung will be highly desirable in addition to 
systemic delivery. Beside direct application of gene 
transfer vector, ex vivo cytokine gene transfer to peri- 
pheral blood monocytes also holds promise. Since 
macrophages within granulomas have a fast turn-over 
rate and the local replenishment of these cells may 
depend upon a continuing influx of peripheral blood 
monocytes, transfusion of monocytes transduced with 
cytokine genes may target the site of infection. 
Cytokines in experimental models of antigen- 
induced allergic airways inflammation 
Asthma is an antigen-mediated chronic airways 
inflammatory disease. The prevalence of this disease in 
the Western world has been rising in the last twenty 
years. Although not always life-threatening, most cases 
of asthma are incurable. Both the direct and indirect 
costs from asthma-related health operations are all but 
enormous (Seaton, 1994). The failure to effectively 
control this disease owes primarily to the lack of our 
understanding of critical pathogenic events. In the last 
several years, progress has been made in understanding 
the role of cytokines in the pathogenesis of asthma by 
using mouse models of asthmatic inflammation. 
Although these models may not completely duplicate the 
pattern of airways physiologic changes and the 
pathologic course of human asthma (there has been a 
lack of mouse models of chronic asthma), they allow to 
dissect the cellular and molecular events underpinning 
airways eosinophilic inflammation, a characteristic 
feature of asthmatic airways (Seminario and Gleich, 
1994). Although the protocol used to set up mouse 
models varies slightly between laboratories, the basic 
scheme is similar. We have established a mouse model 
of antigen-induced allergic airways inflammation by two 
intraperitoneal sensitizations with ovalbumin (OVA), 5 
days apart, and OVA aerosol challenge 12 days later 
twice on the same day. There was marked margination of 
eosinophils and mononuclear cells within the pulmonary 
vasculature as early as 3h post-OVA challenge, 
perivascular accumulation of these cells by 12h and 
marked eosinophil infiltration around bronchi and 
bronchioles (Ohkawara et al., 1997). The peak of such 
cellular responses was around 3 days. While there was a 
lack of evidence of overt epithelial damages such as 
discontinued epithelia and naked basement membrane, 
epithelial goblet cell hyperplasia was evident. Such 
histologic changes faded markedly by day 21, suggesting 
a self-limiting nature of responses elicited by the current 
protocol. A chronic inflammatory process including 
certain degrees of airways fibrotic reactions have been 
observed in a model elicited by using a protocol that 
involves repeated OVA challenges (Blyth et al., 1996). It 
should be pointed out that eosinophils are not the only 
cell type infiltrating the airways and the other cell types 
also increased including lymphocytes, macrophages and 
neutrophils (Ohkawara et al., 1997). This feature has 
also been noticed in human cases (Howarth et al., 1994). 
Since eosinophils represent a very small fraction of total 
peripheral blood leukocytes in both human and rodents, 
the increased number of eosinophils in the bone marrow 
and peripheral blood may represent an important event 
preceding eosinophil infiltration in the lung. Indeed, we 
observed a twin-peak of peripheral blood eosinophilia, 
one at 7 days post-second sensitization and one at 3 and 
9 days post-OVA challenge. The kinetics of bone 
marrow eosinophilia were very similar to those in the 
peripheral blood. These findings suggest the importance 
of  events in the peripheral compartments in the 
development of airways eosinophilia. 
The development of airways eosinophilia in asthma 
is an immunologically mediated event. It is generally 
believed that lymphocytes, both B and Th2 cells, play a 
critical role in the initiation of airways inflammation. 
The mechanisms driving the initial Th2 differentiation of 
T progenitor cells are still unclear but may involve IL-4 
released from CD4+/NKl.1+ cells which appear to be 
selected through the interaction with CD1 molecules on 
antigen presenting cells (Mosmann and Sad, 1996; 
Spinozzi et al., 1998). Upon reexposure to the antigen, 
antigen-presenting cells (APC) present immunogenic 
epitopes to specific T memory cells at the airway 
mucosal site and regional lymph nodes. Activation of T 
cells likely requires not only the antigen presentation by 
APC but also the cognate interaction between T cells 
and APC via CO-stimulatory molecules CD28lB7, and 
gp391CD40. It is believed that TNFa, IL-4, IL-5 and 
GM-CSF as well as chemokines released from activated 
Th2 cells play important roles in the development of 
airways eosinophilic inflammation in asthma (Robinson 
et al., 1993; Seminario and Gleich, 1994; Lukacs et al., 
1996). To dissect the role of cytokines during antigen- 
induced allergic airways eosinophilia, we examined 
cytokine profiles both in the lung and peripheral blood. 
Right after second i.p. sensitization, the circulatory level 
of IL-5 was markedly elevated, thus likely accounting 
for the first wave of peripheral blood eosinophilia 
detected 4 days after second sensitization (Ohkawara et 
al., 1997). This raised IL-5 declined to the baseline prior 
to aerosol challenge. Upon aerosol challenge, the level in 
BAL of TNFa quickly reached a peak in the first several 
hours, perhaps reflecting a contribution from mast cells. 
This was followed by an increase in IL-4 and IL-5 which 
peaked and subsequently declined at days 1 and 5,  
respectively, post-challenge. The kinetics of these 
cytokines correlated well with the development of 
airways eosinophilia which became maximal at about 
day 3. Of interest, the circulating levels of IL-4 and IL-5 
also increased to levels similar to those in the lung. 
However, two differences were noticed: these cytokines 
peaked earlier than those in the lung; the raised levels 
fell much quicker. These suggest that the circulating IL- 
4 and IL-5 may have derived, at least in part, from 
lymphoid tissues outside the lung parenchyma. The level 
of GM-CSF, either in the circulation or in the lung, was 
increased to a much lower degree, than IL-4 or IL-5. 
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This does not appear to agree with the findings from 
human studies (Robinson et al., 1993). IL-5 seems to 
play a much more prominent role than GM-CSF in the 
development of allergic airways inflammation. Indeed, 
the important role of IL-5 in the development of 
eosinophilia has been suggested by evidence from 
studies using monoclonal antibodies to IL-5 or IL-5 
deficient mice. Systemic administration of anti-IL-5 
reduced OVA-induced airways eosinophilia (Kung et al., 
1995). I L - ~ - / -  mice failed to develop airways eosino- 
philia elicited by OVA sensitization and challenge unless 
1L-5 transgene was delivered into the lung (Foster et al., 
1996). Local overexpression in the lung of IL-5, in 
contrast to systemic overexpression of this cytokine 
(Dent et al., 1990), induced profound airways eosino- 
philia and hypersensitivity in transgenic mice (Lee et al., 
1997). Of note, as a consequence of local overproduction 
by airway epithelial cells in this model, there were 
markedly elevated circulating levels of IL-5 and 
increased eosinopoiesis in the bone marrow. Systemic 
overexpression of GM-CSF only induced mild 
peripheral blood eosinophilia with striking macrophage 
accumulation and activation (Lang et al., 1987; Gearing 
et al., 1989), whereas local overexpression in the lung of 
GM-CSF induced only type I1 alveolar epithelial 
hyperplasia but not airways eosinophilia (Huffman Reed 
et al., 1997). It should not be surprising that IL-5 has a 
relatively specific effect on eosinophils whereas GM- 
CSF has a much more broad spectrum of biologic effects 
on various leukocytes due to differential receptor 
distribution (Xing et al., 1996a). One reason why local 
lung GM-CSF did not induce any airways eosinophilia 
could be that the circulatory level of GM-CSF was not 
adequate enough to mobilize eosinophil progenitors in 
the bone marrow. Indeed, compared to IL-5 content in 
the lung (Lee et al., 1997), the level of GM-CSF was 
about 500 times lower (Huffman Reed et al., 1997). This 
notion is supported by our recent findings that over- 
expression of GM-CSF in rat airways epithelial cells by 
a transient transgene approach led to not only macro- 
phage accumulation but prominent airways eosinophilia 
(Xing et al., 1996b). It was noted that in this model 
circulating transgene product GM-CSF that leaked from 
the lung caused a significant peripheral blood eosino- 
philia. Similar approaches also induced airways 
eosinophilia in mouse lung but in a delayed fashion 
(Wang et al., 1998a). Thus, in these transgene models, it 
appears that both local and systemic signals are required 
for the onset of airways eosinophilia with local IL-5 or 
GM-CSF serving as a chemotactic force to peripheral 
blood eosinophils (Resnick and Weller, 1993) and 
systemic IL-5 or GM-CSF as an eosinopoietic factor 
acting on the bone marrow. It should be pointed out that 
the local level of a given transgene product in the lung 
may be much higher than that detected during the course 
of allergic airways inflammation. For instance, the 
maximal level of IL-5 in BAL induced by OVA 
challenge is mostly in pglml ranges. Compared to 
chemokines, IL-5 or GM-CSF is chemotactic to eosino- 
phils in vitro only at higher concentrations (Resnick and 
Weller, 1993). It is therefore likely that the levels in the 
lung of IL-5 or GM-CSF detected during allergic 
inflammation are not by themselves sufficient to be 
chemotactic to eosinophils. The question is then what is 
the function of these locally present hematopoietic 
cytokines during antigen-induced airways inflammation. 
We have recently obtained evidence that GM-CSF 
transgene expression in mouse lung induces macrophage 
activation and dendritic cell differentiation as indicated 
by increased surface expression of MHC 11, B7 and 
CDllc, thus implicating GM-CSF in enhancing antigen 
presentation and antigen-specific immune responses in 
the lung (Wang et al., 1998a). The requirement of GM- 
CSF in antigen-mediated T cell immune responses has 
been observed in GM-CSF-1- mice (Wada et al., 1997). 
Regarding the role of local IL-5 in the lung during 
allergic airways inflammation, we have recently 
observed that there is a lack of airways eosinophilia 
induced by OVA in IL-5-1- mice but airways eosinophilia 
can be reconstituted by intramuscular IL-5 gene transfer 
(Wang et al., 1998b). Such reconstitution was always 
accompanied by a bone marrow and peripheral blood 
eosinophilia. On the contrary, intrapulmonary IL-5 
transgene expression, when compartmentalized to the 
lung, failed to do so. Of importance, the levels in the 
lung of IL-4 and chemokines eotaxin and MIP-la were 
similar in both IL-S+/+ and IL-5-1- mice. So was the 
extent of neutrophilia and lymphocytic responses. These 
findings suggest that systemic but not local, IL-5, 
together with eosinophil chemokines play an important 
role in the initiation of airways eosinophilia (Fig. 3). The 
findings from these studies shall provide important 
mechanistic insights into key events in allergen-induced 
airways eosinophilic inflammation. We have recently 
found that in addition to its critical role in IgE isotype 
switch, IL-4 together with T N F a  plays a role in 
upregulating VCAM- 1 expression by pulmonary 
endothelium which is required for the initiation of OVA- 
induced airways eosinophilia as shown in CD40 ligand 
knock-out mice (Lei et al., 1998). In addition, IL-4, 
when overexpressed in mouse lung, also induces 
profound airways eosinophilia and this effect is likely 
through its direct chemotactic activities (Dubois et al., 
1994) and induction of chemokines. IL-4 induced the 
release of MIP- la  and MCP-1, suggesting that IL-4 
contributes not only to the development of airways 
eosinophilia but mononuclear cell infiltration seen in the 
lung during asthmatic inflammation (Waldhauser et al., 
1998). 
All of the currently available therapies for asthma 
can only control symptoms. It remains t o  be seen 
whether a better-than-steroid therapeutic modality will 
be developed. With increasing understanding of the 
pathogenesis of asthma, targeted therapeutic strategies 
may be developed to intervene selected key events or 
molecules ranging from antigen presentation, T cell 
activation, Th2 cytokines, eosinophil differentiation in 
the bone marrow, to the development of airways 
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inflammatory responses. In this regard, we have recently 
examined the effect of IL-10 by using a transgene 
approach. We found that IL-10 could inhibit the release 
of Th2 cytokines and the extent of airways eosinophilia 
(Ohkawara et al., 1996). IL-10 exerted its inhibitory 
effect perhaps through inhibition of the function of 
antigen-presenting cells and other inflammatory cell 
types. 
Cytokines in experimental models  of pulmonary 
fibrosis 
Pulmonary fibrosis is a pathologic sequela to certain 
insults and represents an excessive form of tissue repair 
by the host who is unable to restore the normal tissue 
architecture that has been severely destructed. Despite of 
heterogeneous etiologies, established pulmonary fibrosis 
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Fig. 3. Role of Th2 cytokines and C-C chemokines in the development 
of antigen-induced allergic airways eosinophilic inflammation. Upon 
interaction of antigen with CD4lNKl.I T cells, the latter release IL-4 
which is a key cytokine in driving Th2 differentiation. After clonal 
expansion, activated antigen-specific Th2 lymphocytes release IL-5, 
GM-CSF, IL-4, TNFa and CC chemokines. GM-CSF in the lung may 
amplify the immune response by further activating antigen-presenting 
cells (APC). Circulatory IL-5 and GM-CSF act on eosinophil andlor other 
myeloid progenitor cells in the bone marrow, releasing increased 
numbers of eosinophils and neutrophils into peripheral blood. Increased 
levels in the lung of TNFa and IL-4 enhance vascular VCAM-1 
expression to promote eosinophil margination. Local CC chemokines 
such as eotaxin serve to attract eosinophils into the airway. 
is characterized by abnormal fibroblast accumulation 
and connective tissue matrix deposition (Gauldie et al., 
1993; Phan, 1995). Since the end-stage pulmonary 
fibrosis is irreversible, understanding the nature of 
earlier cascade events holds the key to the development 
of intervention strategies. A group of Streptomyces 
verticillatus-derived glycopeptides, bleomycin, that is 
used in chemotherapy for cancers, has been widely used 
to establish experimental models of pulmonary fibrosis 
to study pathogenic events (Piguet, 1994). We have 
observed significant accumulation of PMN, lympho- 
cytes, monocytes and eosinophils at day 3 following i.t. 
instillation of bleomycin. The number of PMN steadily 
declined thereafter while the number of other cell types 
remained markedly increased in the following weeks. 
Damage to lung parenchyma, including the airways 
epithelium and alveolar septum was evident even in the 
early phase of inflammation, which was contrary to a 
minimum of tissue destruction seen in endotoxic lung. 
Patches of fibroblastic accumulation and matrix 
deposition were seen from 7 days, progressing into 
diffuse severe fibrotic pathologies in the following 
weeks. Cytokines and growth factors, such as TNFa and 
TGF-B, are believed to play an essential role in the 
development of such overzealous type of tissue repair. 
However, a central issue has remained elusive regarding 
what triggers this fibrogenic cytokine cascade which is 
apparently missing in acute pulmonary inflammatory 
diseases (Jordana et al., 1993; Xing et al., 1994). In the 
latter, many pro-inflammatory cytokines but not fibro- 
genic growth factors are turned on in a limiting fashion 
(Xing et al., 1994). We believe that the nature of 
causative agents dictates the type of tissue responses and 
that severe tissue injury occurs as a result of toxicity of 
fibrogenic agents to the tissue or of the destructive type 
of inflammation elicited by these agents or both. 'The 
sustained severe tissue injury determines, by as yet 
unknown mechanisms, the duration of expression of 
proinflammatory cytokines such as TNFa and the type 
of growth factor responses. It has been demonstrated that 
expression of TNFa mRNA increases over a period of at 
least 14 days with a peak seen between 4 to 7 days post- 
bleomycin administration (Phan and Kunkel, 1992). This 
sustained TNFa expression contrasts the transient nature 
of TNFa expression during acute lung inflammation by 
LPS or Gram-negative bacteria (Xing et al., 1993, 1998; 
Standiford et al., 1996). Expression of TGF-S was 
induced and peaked, almost concurrent with T N F a  
(Raghow et al., 1989; Phan and Kunkel, 1992). The 
critical role of TNFa in triggering fibrotic events is 
suggested from studies using anti-TNFa antibodies 
(Piguet et al., 1989, 1990; Zhang et al., 1997). However, 
TNFa is unlikely the only upstream signal required for 
switching on growth factors. Interestingly, while 
macrophages from bleomycin-treated lungs were found 
to release increased amounts of TNFa in vitro, to the 
best of our knowledge the protein level of this cytokine 
in BAL has not been reported and we found no 
detectable or only marginally increased levels of TNFa 
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in BAL collected at a number of time points (Un- 
published data). Lung cell proliferation and collagen1 
proteoglycan production were found closely associated 
with induction of TGFBl mRNA (Raghow et al., 1989; 
Westergren-Thorsson et al., 1993). There are three 
isoforms of TGF-B, TGF-131/2/3, active in mammals 
(Kelly, 1993). However, most studies have focused on 
the expression of TGF-B1 and the relative contribution 
of each of these three isoforms remains unclear in 
bleomycin models. One recent study suggests a unique 
role of TGF-B1 but not TGFS2 or 3 (Coker et al., 1997) 
whereas the other suggests the involvement of all three 
isoforms (Santana et al., 1995). The former finding is in 
line with observations made in human lung tissues, 
suggesting the importance of TGFBl in the pathogenesis 
of fibrosis and a physiologic role of TGF-B213 in 
maintaining lung homeostasis (Khalil et al., 1996a). The 
concurrent administration of anti-TGFB with bleomycin 
into mouse lung reduced pulmonary collagen deposition, 
thus providing the direct evidence to support the role of 
TGFB in pulmonary fibrosis (Giri et al., 1993). Of note, 
there has been no report on the protein level of TGF-B1 
in BAL. Since there are both inactive and active forms 
of TGF-B molecules (Sime et al., 1997a,b),  ideal 
immunodetection assays should differentiate these two 
forms. By using an ELISA detecting total or only active 
TGF-81, we found that the majority of increased 
measurable TGF-B1 in the BAL samples from bleo- 
mycin-treated mouse lung was inactive, indicating the 
difficulty in assessing the regulation of activation of 
TGF-B molecules in models of pulmonary fibrosis. It is 
likely that the active form of TGF-B1 binds to the 
extracellular matrix, a way by which the host controls its 
bioactivity. By using ex vivo approaches, alveolar 
macrophages isolated from rat fibrotic lungs were found 
to spontaneously release active TGF-B1 which involves 
the cleavage of cell-associated latent TGF-B1 by plasmin 
secreted by these cells (Khalil et al., 1996b). I t  appears 
that different cell types can express antigenic TGF-51, 
depending on the stages of pulmonary fibrotic reactions 
(Zhang et al., 1995). In the early stage, epithelia] and 
mononuclear cells and eosinophils expressed TGF-B1 
whereas at later stages eosinophils and fibroblastslmyo- 
fibroblasts became the major sources as shown by in situ 
hybridization techniques. Unfortunately, current in situ 
techniques including immunohistochemistry cannot 
differentiate the two forms of TGF-81. It is of particular 
interest that eosinophils may play a prominent role in 
pulmonary fibrosis. The presence of eosinophils in 
bleomycin-induced fibrotic lung and in human clinical 
situations with prominent fibrotic features including 
ARDS and IPF is a consistent histologic feature and 
recently IL-5 has been implicated in eosinophil 
chemotaxis and activation (Gharaee-Kermani and Phan, 
1997). However, what regulates the expression of this 
Th2-type cytokine during pulmonary fibrotic responses 
is unclear. IL-5 is primarily produced by T cells and this 
study has not yet pinned down the precise nature of 
mononuclear cells that were found localizing IL-5. I t  
would be of interest to find out whether GM-CSF and 
IL-4 and eosinophil-specific chemokines are also 
induced in this model. In addition to the aforementioned 
cytokines, there is recent evidence implicating the other 
growth factors PDGF and IGF, and chemokines MIP- l a  
and MCP-1, in the pathogenesis of bleomycin-induced 
pulmonary fibrosis (Smith et al., 1994; Zhang et al., 
1994; Maeda et al., 1996). The role of lymphocytes in 
the development of bleomycin-induced fibrosis remains 
to be clarified. It was found that the majority of 
infiltrating lymphocytes were CD4+ T cells with the rest 
being CD8+ and y/6 T cells (Braun et al., 1996). 
Elimination of CD4 or CD8 T cells did not seem to 
affect the final fibrotic outcome. In addition to macro- 
phages, PMN, lymphocytes and eosinophils, the number 
of mast cells was also increased. These cells have been 
shown to be part of the fibrogenic constellation in  a mast 
cell-deficient model (O'Brien-Ladner et al., 1993). 
To examine the role of cytokines in the pathogenesis 
of pulmonary fibrosis, we have established models of 
cytokine transgene expression directed to the respiratory 
epithelium by using adenoviral -mediated gene transfer 
technologies (Xing et al., 1996a; Sime et al., 1997a). 
Different from lung specif ic  transgenic models 
(Korflhagen et  al., 1994; Miyazaki et al . ,  1995), 
adenoviral-mediated lung transgene expression is 
achieved in adult animals in a sustained but relatively 
transient fashion, a situation that mimics events 
occurring during inflammatory responses in humans. 
The limitation of these models is that the biologic events 
induced by transgene product are taking place in the 
lung over a viral infection background. By using these 
models, we have demonstrated the fibrogenic effect of 
TNFa  in the lung (Sime et al., 1998). These effects 
appears to correlate with a mild degree of induction of 
TGF-B1 release in the lung elicited by prolonged TNFa 
expression. We have also provided the first evidence that 
the active, but not the latent, form of TGF-B1 has potent 
fibrogenic effects in the lung (Sime et al., 1997b). 
Overexpression of active TGF-B1 in rat lung led to the 
formation of an aggressive type of pulmonary fibrosis 
with massive fibroblastic and myofibroblastic accumula- 
tion and connective tissue matrix protein deposition. 
These models will be invaluable for us to understand the 
mechanisms by which the latent TGF-IJ is activated in 
the lung and to test intervention strategies targeting 
TGF-B-mediated connective tissue metabolism. 
Overexpression of GM-CSF, used to be deemed as a 
hematopoietic growth factor, caused macrophage and 
eosinophil accumulation followed by granulation tissue 
formation and appearance of fibrotic patches in the lung 
(Xing et al., 1996b). The fibrotic sequela appeared to 
involve a cascade of events including macrophage and 
eosinophil activation, lung injury, TGF-B1 upregulation, 
myofibroblast accumulation and granulation tissue 
formation (Xing et al., 1997b). Of interest, TNFa was 
not involved in these processes in a significant manner. 
Intradermal GM-CSF trans-gene expression also elicited 
subepidermal fibrosis characterized by fibroblast 
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hyperplasia (Xing et al., 1 9 9 7 ~ ) .  Fibrogenic activities of 
GM-CSF were also demonstrated in the subcutaneous 
tissue following delivery of recombinant GM-CSF by a 
minipump (Rubbia-Brandt et al., 1991). Thus, GM-CSF 
may serve as a macrophage activator to release TGF-B1, 
downstream of T N F a  response. Together, these findings 
provide important experimental evidence to support a 
critical role of TGF-B1 and myofibroblasts in the patho- 
genesis of pulmonary fibrosis. 
Pu lmonary  f ib ros i s  in h u m a n s  is  a c h r o n i c  
inflammatory disease and, in most cases, when clinically 
manifested, the disease is already in its later stages. Most 
patients with pulmonary fibrosis respond poorly to the 
current antifibrotic agents (Hunninghake and Kalica, 
1995). The challenging issue is whether we can develop 
therapeutic strategies that are able to modulate the later 
fibrotic events, particularly TGF-B-mediated events. 
Development of anti-growth factor agents may hold 
great  p romise  in th is  regard .  Recent ly ,  t r ansgene  
expression of decorin, a TGF-B1 inhibitor, has been 
shown to prevent renal fibrosis in rats (Isaka et  al., 
1996). We are currently exploring the usefulness of 
adenoviral gene transfer vectors for decorin or  LAP 
(TGF-B latency associated peptide) in ameliorating 
pulmonary fibrosis in experimental models. 
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